Combangio, Inc

Antheia Inc, based in Menlo Park, CA, is a leading biotechnology company specializing in fermentation and synthetic biology. With a strong focus on innovation and research, Antheia develops comprehensive fermentation processes and data collection systems, led by their experienced team of experts in microbial metabolism and fermentation process development. Under the leadership of their Head of Strategy, Partnerships, and Finance, Antheia also collaborates with various organizations to establish global standards for AI in healthcare. Additionally, their Biology team, headed by an industry veteran, specializes in strain and protein engineering, while their Downstream Processing division is led by an expert in the field. Antheia is dedicated to advancing the field of biotechnology through cutting-edge research and development.Generated from the website

Adicet Bio, based in Menlo Park, CA, is a biotechnology company specializing in off-the-shelf T cell therapy for autoimmune diseases and cancer. Their focus on gamma delta T cells represents a cutting-edge approach to immune cell therapy. Through their proprietary cell platform, Adicet is developing allogeneic genetically modified gamma delta T cells that target tumors selectively. The company's recent preclinical data presentations and participation in industry conferences highlight their commitment to advancing innovative treatments in the field of gene and cell therapy. Generated from the website

Allakos Inc, based in San Carlos, CA, is a biopharmaceutical company dedicated to developing therapeutic antibodies that target immunomodulatory receptors on immune effector cells involved in allergy, inflammatory, and proliferative diseases. Their lead programs focus on inhibiting mast cell and eosinophil activation, as these cells play a pathogenic role in various inflammatory conditions. With a focus on novel biology, Allakos is conducting Phase 2 studies in Chronic Spontaneous Urticaria and Atopic Dermatitis, utilizing investigational monoclonal antibodies such as Lirentelimab (AK002) to deplete eosinophils and inhibit mast cells, and AK006 to selectively and potently inhibit mast cells, including KIT mediated signaling. Their commitment lies in addressing the needs of patients suffering from chronic inflammatory diseases through innovative therapeutic approaches.Generated from the website